Literature DB >> 19826641

Learning the lessons of antitumour necrosis factor therapy-associated psoriasis.

Matt Shale1, Subrata Ghosh.   

Abstract

Psoriasis or psoriasiform skin lesions, as an adverse effect of treatment with antitumor necrosis factor antibody therapy, have been described relatively recently. Patients with these lesions have no personal or family history of psoriasis. In a small number of cases, an association with Chlamydia has been suggested. The skin lesions may disappear on discontinuation of therapy or, in the majority of cases, even if antitumor necrosis factor antibody therapy is continued. Therefore, withdrawal of therapy is generally not required for this adverse effect but referral to a dermatologist may be desirable for confirmation of diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826641      PMCID: PMC2776609          DOI: 10.1155/2009/514618

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  27 in total

1.  Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct?

Authors:  G Michaëlsson; U Kajermo; A Michaëlsson; E Hagforsen
Journal:  Br J Dermatol       Date:  2005-12       Impact factor: 9.302

2.  Psoriasiform drug eruptions under anti-TNF treatment of arthritis are not true psoriasis.

Authors:  Julien Seneschal; Sebastian Lepreux; Marie-Laure Bouyssou-Gauthier; Isabelle Héliot-Hosten; Andra Economu; Joel Dehais; Thierry Schaeverbeke; Alain Taïeb
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

3.  Psoriasiform eruptions during anti TNF-alpha treatment: psoriasis or not?

Authors:  Julien Seneschal; Sébastien Lepreux; Brigitte Milpied; Thierry Schaeverbeke; Alain Taïeb
Journal:  Arch Dermatol       Date:  2007-12

4.  Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

Authors:  Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05       Impact factor: 11.382

5.  Early cytokine profiles in the joint define pathogen clearance and severity of arthritis in Chlamydia-induced arthritis in rats.

Authors:  Robert D Inman; Basil Chiu
Journal:  Arthritis Rheum       Date:  2006-02

Review 6.  Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.

Authors:  Gillian C de Gannes; Mehran Ghoreishi; Janet Pope; Anthony Russell; David Bell; Stewart Adams; Kamran Shojania; Magdalena Martinka; Jan P Dutz
Journal:  Arch Dermatol       Date:  2007-02

7.  Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B.

Authors:  Ioannis Ketikoglou; Stelios Karatapanis; Ioannis Elefsiniotis; Georgia Kafiri; Antonios Moulakakis
Journal:  Eur J Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.328

Review 8.  Triggering psoriasis: the role of infections and medications.

Authors:  Lionel Fry; Barbara S Baker
Journal:  Clin Dermatol       Date:  2007 Nov-Dec       Impact factor: 3.541

Review 9.  Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Authors:  Uwe Wollina; Gesina Hansel; André Koch; Jaqueline Schönlebe; Erich Köstler; Gunter Haroske
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

10.  Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

Authors:  Frank O Nestle; Curdin Conrad; Adrian Tun-Kyi; Bernhard Homey; Michael Gombert; Onur Boyman; Günter Burg; Yong-Jun Liu; Michel Gilliet
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

View more
  3 in total

1.  Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis.

Authors:  T Cabaleiro; R Prieto-Pérez; R Navarro; G Solano; M Román; D Ochoa; F Abad-Santos; E Daudén
Journal:  Pharmacogenomics J       Date:  2015-07-21       Impact factor: 3.550

2.  Infliximab-induced intertriginous psoriasis in patient with Crohn's disease.

Authors:  Federica Mola; Alberico Motolese
Journal:  Dermatol Reports       Date:  2011-10-03

3.  Resistant palmoplantar lesions in patients of psoriasis: evaluation of the causes and comparison of the frequency of delayed-type hypersensitivity in patients without palm and sole lesions.

Authors:  Nawaf Al-Mutairi; Tarek O Abdalla; Tarek M Nour
Journal:  Med Princ Pract       Date:  2014-09-03       Impact factor: 1.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.